QQQ   387.29 (+0.25%)
AAPL   193.42 (+2.11%)
MSFT   372.52 (+0.92%)
META   318.29 (-0.54%)
GOOGL   130.99 (+1.33%)
AMZN   146.88 (+1.41%)
TSLA   238.72 (+1.33%)
NVDA   465.66 (+2.33%)
NIO   7.43 (+1.37%)
BABA   72.39 (-0.88%)
AMD   118.38 (-0.16%)
T   17.22 (+3.36%)
F   10.60 (-0.93%)
MU   73.69 (-0.81%)
CGC   0.67 (-11.90%)
GE   120.24 (-1.06%)
DIS   90.80 (-1.32%)
AMC   7.03 (-6.15%)
PFE   29.09 (-0.65%)
PYPL   57.92 (-3.22%)
XOM   100.44 (-1.94%)
QQQ   387.29 (+0.25%)
AAPL   193.42 (+2.11%)
MSFT   372.52 (+0.92%)
META   318.29 (-0.54%)
GOOGL   130.99 (+1.33%)
AMZN   146.88 (+1.41%)
TSLA   238.72 (+1.33%)
NVDA   465.66 (+2.33%)
NIO   7.43 (+1.37%)
BABA   72.39 (-0.88%)
AMD   118.38 (-0.16%)
T   17.22 (+3.36%)
F   10.60 (-0.93%)
MU   73.69 (-0.81%)
CGC   0.67 (-11.90%)
GE   120.24 (-1.06%)
DIS   90.80 (-1.32%)
AMC   7.03 (-6.15%)
PFE   29.09 (-0.65%)
PYPL   57.92 (-3.22%)
XOM   100.44 (-1.94%)
QQQ   387.29 (+0.25%)
AAPL   193.42 (+2.11%)
MSFT   372.52 (+0.92%)
META   318.29 (-0.54%)
GOOGL   130.99 (+1.33%)
AMZN   146.88 (+1.41%)
TSLA   238.72 (+1.33%)
NVDA   465.66 (+2.33%)
NIO   7.43 (+1.37%)
BABA   72.39 (-0.88%)
AMD   118.38 (-0.16%)
T   17.22 (+3.36%)
F   10.60 (-0.93%)
MU   73.69 (-0.81%)
CGC   0.67 (-11.90%)
GE   120.24 (-1.06%)
DIS   90.80 (-1.32%)
AMC   7.03 (-6.15%)
PFE   29.09 (-0.65%)
PYPL   57.92 (-3.22%)
XOM   100.44 (-1.94%)
QQQ   387.29 (+0.25%)
AAPL   193.42 (+2.11%)
MSFT   372.52 (+0.92%)
META   318.29 (-0.54%)
GOOGL   130.99 (+1.33%)
AMZN   146.88 (+1.41%)
TSLA   238.72 (+1.33%)
NVDA   465.66 (+2.33%)
NIO   7.43 (+1.37%)
BABA   72.39 (-0.88%)
AMD   118.38 (-0.16%)
T   17.22 (+3.36%)
F   10.60 (-0.93%)
MU   73.69 (-0.81%)
CGC   0.67 (-11.90%)
GE   120.24 (-1.06%)
DIS   90.80 (-1.32%)
AMC   7.03 (-6.15%)
PFE   29.09 (-0.65%)
PYPL   57.92 (-3.22%)
XOM   100.44 (-1.94%)

Ritter Pharmaceuticals Stock Price, News & Analysis (NASDAQ:RTTR)

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$0.69
▼
$0.74
50-Day Range
$0.45
▼
$4.09
52-Week Range
$0.15
▼
$1.27
Volume
10,244 shs
Average Volume
14.23 million shs
Market Capitalization
$33.02 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisCompetitorsHeadlinesSocial Media

RTTR stock logo

About Ritter Pharmaceuticals Stock (NASDAQ:RTTR)

Ritter Pharmaceuticals, Inc. develops and sells novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b clinical trial for the reduction of symptoms associated with lactose intolerance. The company's product, RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon, thereby adapting the gut microbiome to assist in digesting the lactose that reaches the large intestine. The company was formerly known as Ritter Natural Sciences, LLC and changed its name to Ritter Pharmaceuticals, Inc. in September 2008. Ritter Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Los Angeles, California.


RTTR Stock News Headlines

September 15, 2023 | health.usnews.com
Kristen Ritter
July 8, 2023 | health.usnews.com
Dr. Harold K. Ritter
December 5, 2023 | Autonomix (Ad)
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
July 1, 2023 | bizjournals.com
Denver Business Journal welcomes new tech reporter
April 10, 2023 | usatoday.com
Jason Ritter and Drew Barrymore's raw conversation on her show may matter more than you think
March 29, 2023 | thestreet.com
Ritter Pharmaceuticals Changing the Game With Lactose Intolerance Treatment
March 18, 2023 | finance.yahoo.com
Global Microbiome Market Report 2023: Major Players Include MicroBiome Therapeutics, Seres Therapeutics, Enterome Bioscience and Second Genome
January 19, 2023 | yahoo.com
Melanie Lynskey's husband Jason Ritter will join her in Yellowjackets this season
December 5, 2023 | DTI Trader (Ad)
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
November 16, 2022 | finance.yahoo.com
Microbiome Clinical Trial Pipeline Space Brims with Novel Emerging Therapies with 130+ Key Players Working in the Domain | DelveInsight
May 24, 2021 | au.finance.yahoo.com
Docbot Closes Series A Financing Led by Khosla Ventures and Appoints Andrew J. Ritter as CEO
April 18, 2021 | investing.com
Qualigen Therapeutics Inc (QLGN)
June 10, 2020 | finance.yahoo.com
Qualigen Therapeutics Signs Exclusive License Agreement with the University of Louisville, Plans to Develop AS1411 for the Treatment of COVID-19
June 4, 2020 | finance.yahoo.com
Qualigen Therapeutics Receives U.S. Patent Notice of Allowance for its STARS™ Technology
May 22, 2020 | seekingalpha.com
Ritter to complete Qualigen tie-up today
May 22, 2020 | apnews.com
Ritter Pharmaceuticals, Inc. Announces Expected Closing of Merger Transaction with Qualigen, Inc.
May 22, 2020 | finance.yahoo.com
Ritter Pharmaceuticals, Inc. Announces Expected Closing of Merger Transaction with Qualigen, Inc.
May 19, 2020 | finance.yahoo.com
Ritter Pharmaceuticals, Inc. Announces Stockholder Approval of Proposals Required for Merger Transaction with Qualigen, Inc.
May 14, 2020 | finance.yahoo.com
Ritter Pharmaceuticals, Inc. Announces Adjournment of its Special Meeting
May 11, 2020 | www.benzinga.com
Ritter Pharmaceuticals Regains Compliance with Nasdaq's Stockholders' Equity Requirement for Continued Listing
May 11, 2020 | finance.yahoo.com
Ritter Pharmaceuticals Regains Compliance with Nasdaq’s Stockholders’ Equity Requirement for Continued Listing
May 7, 2020 | www.nasdaq.com
RTTR Ritter Pharmaceuticals, Inc. Common Stock
May 7, 2020 | www.msn.com
66 Biggest Movers From Yesterday
May 7, 2020 | www.benzinga.com
Thinking about buying stock in Stemline Therapeutics, KLX Energy, Trinity Biotech, Tilray, or Ritter Pharmaceuticals?
May 6, 2020 | finance.yahoo.com
Leading Independent Proxy Advisory Firms Recommend Ritter Pharmaceuticals Shareholders Vote in Favor of its Merger and Each of the Merger Proposals
May 1, 2020 | finance.yahoo.com
Ritter Pharmaceuticals Reports Financial Results for the First Quarter Ended March 31, 2020
April 28, 2020 | finance.yahoo.com
Ritter Pharmaceuticals, Inc. Urges Stockholders to Vote Now on Proposed Merger with Biotech Company, Qualigen Inc.
See More Headlines
Receive RTTR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ritter Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/01/2020
Today
12/05/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RTTR
CUSIP
N/A
CIK
1460702
Web
www.ritterpharmaceuticals.com
Phone
310-203-1000
Fax
N/A
Employees
7
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-10,130,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
-162.05%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.67
Quick Ratio
3.67

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.10 per share
Price / Book
7.01

Miscellaneous

Outstanding Shares
46,153,000
Free Float
N/A
Market Cap
$32.33 million
Optionable
Not Optionable
Beta
-0.43
7 Stocks to Buy And Hold Forever Cover
7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Mr. Ira Eliot Ritter (Age 70)
    Co-Founder, Exec. Chairman & Chief Strategic Officer
  • Mr. Andrew J. Ritter (Age 36)
    Co-Founder, CEO, Pres, Corp. Sec. & Director
  • Mr. Michael D. Step (Age 59)
    Consultant & Director
  • Mr. John W. Beck CPA (Age 59)
    CPA, Chief Financial Officer
  • Ms. Ellen F. Mochizuki (Age 52)
    Consultant

Key Competitors

View All Competitors














RTTR Stock Analysis - Frequently Asked Questions

How were Ritter Pharmaceuticals' earnings last quarter?

Ritter Pharmaceuticals Inc (NASDAQ:RTTR) released its earnings results on Friday, May, 1st. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.04) by $0.01.

When did Ritter Pharmaceuticals' stock split?

Ritter Pharmaceuticals shares reverse split on Friday, March 23rd 2018. The 1-10 reverse split was announced on Thursday, March 22nd 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, March 22nd 2018. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Ritter Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ritter Pharmaceuticals investors own include Endologix (ELGX), Chipotle Mexican Grill (CMG), Aegean Marine Petroleum Network (ANW), Charles Schwab (SCHW), Genocea Biosciences (GNCA), Hudson Technologies (HDSN), Vicor (VICR), Zoetis (ZTS) and

When did Ritter Pharmaceuticals IPO?

(RTTR) raised $20 million in an IPO on Wednesday, June 24th 2015. The company issued 4,000,000 shares at $5.00 per share. Aegis Capital Corp and Chardan Capital Markets served as the underwriters for the IPO and Barrington Research was co-manager.

This page (NASDAQ:RTTR) was last updated on 12/5/2023 by MarketBeat.com Staff

My Account -